Improving cognitive performance with aromatherapy in young, healthy volunteers is one thing, but how about where it really matters? As I discuss in my video Best Aromatherapy Herb for Alzheimer’s, a group of Japanese researchers had a pie-in-the-sky notion that certain smells could lead to… Read More »Topical Lemon Balm Lotion for Alzheimer’s
Recent Advances in Alzheimer’s Disease Prevention A prominent neurologist reviews what is known (and not known) about recent evidence-based advances in Alzheimer’s Disease prevention. The Doctor Weighs In
Biogen and Eisai said the FDA had accepted and given priority review to their application for aducanumab. The drug will undergo an advisory committee meeting at an undisclosed date. Biogen’s stock rose 10%, but analysts had mixed opinions.
Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $120 million upfront for exclusive global rights to UCB0107, an anti-tau… Read More »Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m
Shots: UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of the therapies, if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for… Read More »Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease
What You Should Know: – Current Health has partnered with Dexcom to add continuous glucose monitoring (CGM) capabilities to its remote patient monitoring (RPM) platform – enhancing care and improving outcomes for diabetics. – Dexcom CGM data will transmit directly into the Current Health wearable… Read More »Current Health, Dexcom Partner to Deliver Continuous, Remote Glucose Monitoring
Biogen, Eisai complete submission of controversial Alzheimer’s drug. The ball is in FDA’s court now.
The FDA has 60 days to decide whether or not to accept the application. An analyst wrote that the agency accepting it with a priority or standard review may signal whether the agency is seriously considering approval or has continued reservations about the amyloid beta-targeting… Read More »Biogen, Eisai complete submission of controversial Alzheimer’s drug. The ball is in FDA’s court now.
Having hypertension in midlife (ages 40 through 60) is associated with elevated risk of cognitive impairment and Alzheimer’s dementia later in life, even more so than having the so-called Alzheimer’s gene. “It is clear that cerebral vascular disease”—that is, hardening of the arteries inside our… Read More »High Blood Pressure May Lead to Low Brain Volume